Literature DB >> 29794412

Validity of a Novel Method for Estimating Low-Density Lipoprotein Cholesterol Levels in Cardiovascular Disease Patients Treated with Statins.

Takeshi Sonoda1, Takuro Takumi1, Masaaki Miyata1, Daisuke Kanda1, Ippei Kosedo1, Satoshi Yoshino1, Mitsuru Ohishi1.   

Abstract

AIM: The Friedewald equation is the standard method for estimating low-density lipoprotein cholesterol (LDL-C) levels [LDL-C(F)] and fixes the ratio of triglyceride (TG) to very LDL-C at 5. However, this has been reported to underestimate LDL-C, particularly in patients with LDL-C <70 mg/dL. A novel method for LDL-C estimation [LDL-C(M)] using an adjustable factor instead of a fixed value of 5 has recently been proposed. The purpose of this study was to validate LDL-C(M) in Japanese patients with cardiovascular disease (CVD) treated with statins.
METHODS: In 385 consecutive CVD patients treated with statins, LDL-C(M) and LDL-C(F) levels were compared with directly measured LDL-C [LDL-C(D)].
RESULTS: Mean LDL-C(D), LDL-C(F), and LDL-C(M) were 81.7±25.5, 76.4±24.6, and 79.9±24.5 mg/dL, respectively. In all patients, both LDL-C(F) and LDL-C(M) were significantly correlated with LDL-C(D) [LDL-C(F) vs. LDL-C(D): R=0.974, p<0.001; LDL-C(M) vs. LDL-C(D): R=0.987, p<0.001]. In patients with LDL-C(D) <70 mg/dL, LDL-C(M) showed a better correlation with LDLC(D) compared with LDL-C(F) [LDL-C(M) vs. LDL-C(D): R=0.935, p<0.001; LDL-C(F) vs. LDLC(D): R=0.868, p<0.001]. In contrast, the correlation of LDL-C(D) with LDL-C(M) or LDL-C(F) was similar in patients with LDL-C(D) ≥70 mg/dL.
CONCLUSIONS: In Japanese patients with CVD treated with statins, LDL-C level estimated by this novel method might be more accurate than those estimated using the Friedewald equation for LDL-C levels <70 mg/dL.

Entities:  

Keywords:  Cardiovascular disease; Friedewald equation; Low-density lipoprotein cholesterol; Martin method; Statin

Mesh:

Substances:

Year:  2018        PMID: 29794412      PMCID: PMC6055036          DOI: 10.5551/jat.44396

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  26 in total

1.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

2.  Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.

Authors:  Antonio J Vallejo-Vaz; Michele Robertson; Alberico L Catapano; Gerald F Watts; John J Kastelein; Chris J Packard; Ian Ford; Kausik K Ray
Journal:  Circulation       Date:  2017-09-06       Impact factor: 29.690

3.  Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension Studies.

Authors:  Peter P Toth; Olivier Descamps; Jacques Genest; Naveed Sattar; David Preiss; Ricardo Dent; Constantine Djedjos; Yuna Wu; Michelle Geller; Magdalena Uhart; Ransi Somaratne; Scott M Wasserman
Journal:  Circulation       Date:  2017-03-01       Impact factor: 29.690

4.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

Review 5.  2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

Authors:  Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur
Journal:  Can J Cardiol       Date:  2013-02       Impact factor: 5.223

6.  A clinical comparison of calculated versus direct measurement of low-density lipoprotein cholesterol level.

Authors:  Cameron C Lindsey; Maqual R Graham; Thomas P Johnston; Chelsea G Kiroff; Anna Freshley
Journal:  Pharmacotherapy       Date:  2004-02       Impact factor: 4.705

7.  A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study.

Authors:  D M DeLong; E R DeLong; P D Wood; K Lippel; B M Rifkind
Journal:  JAMA       Date:  1986-11-07       Impact factor: 56.272

8.  Effects of total cholesterol and triglyceride on the percentage difference between the low-density lipoprotein cholesterol concentration measured directly and calculated using the Friedewald formula.

Authors:  Kyung Ran Jun; Hae-Il Park; Sail Chun; Hyosoon Park; Won-Ki Min
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

9.  Validity of a Novel Method for Estimation of Low-Density Lipoprotein Cholesterol Levels in Diabetic Patients.

Authors:  Hideto Chaen; Shigesumi Kinchiku; Masaaki Miyata; Shoko Kajiya; Hitoshi Uenomachi; Toshinori Yuasa; Kunitsugu Takasaki; Mitsuru Ohishi
Journal:  J Atheroscler Thromb       Date:  2016-09-02       Impact factor: 4.928

Review 10.  Lipid Lowering Therapy and Circulating PCSK9 Concentration.

Authors:  Tsuyoshi Nozue
Journal:  J Atheroscler Thromb       Date:  2017-08-14       Impact factor: 4.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.